💊 We conclude that ketamine may induce psychotic-like symptoms by disrupting consciousness.

📣 Please enjoy, share, and give feedback!

Many thanks to my colleagues who supported me in this epic tale!
Raphaël Gaillard, @standehaene.bsky.social, @thomasandrillon.bsky.social and Alexandre Salvador

👀 We used a visual masking paradigm and found that healthy volunteers under ketamine were less able to perceive a digit.

🧠 These effects were related to a decreased early brain activity in EEG (N1) and to the intensity of experienced psychotic-like symptoms.

Thank you so much @haunted.audio, it is an amazing series!

This amazing series by Tim Hayward and Richard Ward @haunted.audio (🙏🙏🙏) also featured renowned neuroscientists such as @christimmermann.bsky.social, @katrinpreller.bsky.social, Gul Dölen, as well as nurses, historians, philosophers, sociologists, etc.

Enjoy! 🎧

In the first episode, I explain what is specific about psychedelics as treatment in psychiatry.
In last episode, dealing about the future of psychedelics, I talk about the possible dissociation between the psychedelic experience and the therapeutic effects:

www.bbc.co.uk/programmes/m...

🙏 A huge thanks to my co-authors Selim Tümkaya, Bengü Yücens, Mohamed Gunduz and Maxime Maheu @maheump.bsky.social

In sum :
✅ Consciousness disruption translates into various symptomatic expressions according to the psychiatric disorder
✅ In patients with OCD, consciousness disruption delineates two distinct subgroups in terms of cognitive deficits and clinical features

‼️ Patients with SCZ have consciousness disruption in relation with positive symptoms
‼️ Patients with OCD who have a poor insight exhibit similar consciousness deficits as patients with schizophrenia
‼️ Patients with OCD and good insight performed similarly to controls ⤵️

We compared consciousness measures in patients with #OCD and with #schizophrenia as a function of symptom relevant dimensions.

😮 We found pretty surprising results: ⤵️

Thanks to all my collaborators!!

Overall, our results underscore that a univariate data-driven symptom improvement measure can be more sensitive to detect antidepressant action and is specifically associated with baseline neurobehavioral features.

Moreover, improvement was more robustly predicted by baseline neural and clinical features under antidepressant compared to placebo.

However, the intensity of antidepressant and placebo response significantly differs (in previous papers on this dataset, scale level measures of improvement could not distinguish between the two).

We applied principal component analysis (PCA) on the variations of items from multiple clinical scales and strikingly observed a similar pattern of clinical improvement across antidepressant and placebo arms.

We explored clinical response in patients with major depressive disorder from the EMBARC dataset.

A big thank to my colleagues Baptiste Fauvel, @katrinpreller.bsky.social and Raphaël Gaillard

Please find here the link for free access until 27th of July:
authors.elsevier.com/a/1lE1NY3M3l...

Enjoy!!

🧠 No fewer than 81 articles are described in depth and put together to provide an overview of the neurocognitive effects of psilocybin in healthy volunteers and people with medical conditions.

😅 Believe me, it was quite a long journey before it was published in Neuroscience & Biobehavioral Reviews!